ONTX Onconova Therapeutics Inc

Price (delayed)

$0.8751

Market cap

$18.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

-$28.25M

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways ...

Highlights
The EPS has soared by 53% YoY and by 9% from the previous quarter
Onconova Therapeutics's net income has increased by 29% YoY
The quick ratio has increased by 24% year-on-year but it has declined by 16% since the previous quarter
The equity is up by 17% year-on-year but it has declined by 9% since the previous quarter
The company's revenue fell by 4.2% YoY
The gross profit has declined by 4.2% year-on-year

Key stats

What are the main financial stats of ONTX
Market
Shares outstanding
20.9M
Market cap
$18.29M
Enterprise value
-$28.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.48
Price to sales (P/S)
80.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-124.99
Earnings
Revenue
$226,000
EBIT
-$15.36M
EBITDA
-$15.35M
Free cash flow
-$17.04M
Per share
EPS
-$0.77
Free cash flow per share
-$0.82
Book value per share
$1.84
Revenue per share
$0.01
TBVPS
$2.3
Balance sheet
Total assets
$48.07M
Total liabilities
$9.59M
Debt
$0
Equity
$38.48M
Working capital
$41.57M
Liquidity
Debt to equity
0
Current ratio
7.44
Quick ratio
7.21
Net debt/EBITDA
3.03
Margins
EBITDA margin
-6,791.6%
Gross margin
100%
Net margin
-6,797.8%
Operating margin
-7,081.9%
Efficiency
Return on assets
-28.6%
Return on equity
-34.8%
Return on invested capital
N/A
Return on capital employed
-36.9%
Return on sales
-6,797.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ONTX stock price

How has the Onconova Therapeutics stock price performed over time
Intraday
2.11%
1 week
-2.78%
1 month
-24.56%
1 year
-75.14%
YTD
-65.68%
QTD
-0.67%

Financial performance

How have Onconova Therapeutics's revenue and profit performed over time
Revenue
$226,000
Gross profit
$226,000
Operating income
-$16.01M
Net income
-$15.36M
Gross margin
100%
Net margin
-6,797.8%
Onconova Therapeutics's net income has increased by 29% YoY
The net margin has grown by 26% YoY
The company's operating income rose by 25% YoY and by 3.2% QoQ
Onconova Therapeutics's operating margin has increased by 21% YoY and by 3.2% from the previous quarter

Growth

What is Onconova Therapeutics's growth rate over time

Valuation

What is Onconova Therapeutics stock price valuation
P/E
N/A
P/B
0.48
P/S
80.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-124.99
The EPS has soared by 53% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 52% less than its last 4 quarters average of 1.0
The equity is up by 17% year-on-year but it has declined by 9% since the previous quarter
The price to sales (P/S) is 57% lower than the last 4 quarters average of 188.0 and 54% lower than the 5-year quarterly average of 177.4
The company's revenue fell by 4.2% YoY

Efficiency

How efficient is Onconova Therapeutics business performance
ONTX's return on equity has surged by 64% year-on-year and by 4.4% since the previous quarter
ONTX's return on assets has surged by 54% year-on-year and by 3.1% since the previous quarter
The ROS has grown by 26% YoY

Dividends

What is ONTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONTX.

Financial health

How did Onconova Therapeutics financials performed over time
The current ratio has grown by 26% YoY but it has contracted by 14% from the previous quarter
The quick ratio has increased by 24% year-on-year but it has declined by 16% since the previous quarter
The debt is 100% less than the equity
The equity is up by 17% year-on-year but it has declined by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.